BioCentury | Sep 19, 2019
Product Development

Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance. Armed with a fresh $40 million series B round, Anokion S.A. is developing...
BioCentury | Sep 19, 2019
Product Development

Anokion’s autoimmunity platform evolution

When the science suggested the liver, and not the blood, could be the better target tissue for tolerance-inducing autoantigens, Anokion devised a platform around the former. About 18 months after its pivot, the company is...
BioCentury | Sep 12, 2019
Company News

Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015. Versant Ventures, Novartis Venture Fund,...
BioCentury | Sep 7, 2018
Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and...
BioCentury | Jul 20, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is...
BioCentury | Jul 16, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
BioCentury | Apr 7, 2017
Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
BioCentury | Jan 27, 2017
Clinical News

Allogeneic aNK cells: Ph I QUILT-3.018 data

Data from 7 patients with relapsed or refractory AML in the open-label, U.S. Phase I QUILT-3.018 trial showed that 1×10 9 and 3×10 9 IV aNK cells/m 2 led to no dose-limiting toxicities (DLTs) or...
BioCentury | Jan 27, 2017
Clinical News

Allogeneic aNK cells: Preliminary Ph II QUILT-3.009 data

Preliminary data from 3 patients with unresectable stage IIIB or IV MCC in the open-label, U.S. Phase II QUILT-3.009 trial showed that 2x10 9 IV aNK cells/m 2 for 2 consecutive days every 2 weeks...
Items per page:
1 - 10 of 17